

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on \_\_\_\_\_

PATENT  
Attorney Docket No.: 18941H-002911US  
Client Ref. No.: B98-006-3

TOWNSEND and TOWNSEND and CREW LLP

By: \_\_\_\_\_

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

GOODMAN et al.

Application No.: 10/826,812

Filed: April 16, 2004

For: ROBO: A NOVEL FAMILY OF  
POLYPEPTIDES AND NUCLEIC  
ACIDS

Customer No.: 20350

Confirmation No. 1573

Examiner: Olga N. Chernyshev, Ph.D.

Technology Center/Art Unit: 1649

DECLARATION UNDER 37 C.F.R. §  
1.131

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We, Corey S. Goodman, Thomas Kidd, Kevin J. Mitchell, and Guy Tear were at the time of the invention employed by the Regents of the University of California, the assignee of the above-referenced patent application.

We are the co-inventors of the subject matter described and claimed therein.

We obtained the sequence of the extracellular domain, including amino acid residues 68-167, of human Robo-1 prior to April 18, 1997. Attached Exhibits A and B provide evidence of the conception of the invention and its reduction to practice. This work was done by us, or under our supervision.


Exhibit A shows the amino acid sequence of human Robo-1 that we had obtained before April 18, 1997. Exhibit A is a print out of a Microsoft Word file that was electronically archived and last modified before April 18, 1997. Exhibit B shows the contents of the compact disk that contains the file. The dates in the "Date Modified" column have been redacted. Exhibit A is a print out of the highlighted file "H-robo pep.word". This sequence includes the

extracellular domain (five immunoglobulin domains and three fibronectin domains). Amino acids 68-167 of H-Robol pep are the first immunoglobulin domain and correspond to amino acids 68-167 of SEQ ID NO:8 in the application.

In view of the foregoing, we respectfully submit that the evidence provided in this Declaration unequivocally establishes that the basic inventive concept of the claimed invention was conceived of and reduced to practice in this country prior to April 18, 1997.

We further declare that all statements made herein of our knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that any such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 11/30/07

  
Corey S. Goodman

Dated: \_\_\_\_\_

\_\_\_\_\_  
Thomas Kidd

Dated: \_\_\_\_\_

\_\_\_\_\_  
Kevin J. Mitchell

Dated: \_\_\_\_\_

\_\_\_\_\_  
Guy Tear

Appl. No. 10/826,812  
Thomas Kidd, Ph.D.  
Declaration under 37 C.F.R. § 1.131

PATENT

extracellular domain (five immunoglobulin domains and three fibronectin domains). Amino acids 68-167 of H-Robol pep are the first immunoglobulin domain and correspond to amino acids 68-167 of SEQ ID NO:8 in the application.

In view of the foregoing, we respectfully submit that the evidence provided in this Declaration unequivocally establishes that the basic inventive concept of the claimed invention was conceived of and reduced to practice in this country prior to April 18, 1997.

We further declare that all statements made herein of our knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that any such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: \_\_\_\_\_

\_\_\_\_\_  
Corey S. Goodman

Dated: 11/28/07

Tom Kidd  
Thomas Kidd

Dated: \_\_\_\_\_

\_\_\_\_\_  
Kevin J. Mitchell

Dated: \_\_\_\_\_

\_\_\_\_\_  
Guy Tear

Appl. No. 10/826,812  
Thomas Kidd, Ph.D.  
Declaration under 37 C.F.R. § 1.131

PATENT

extracellular domain (five immunoglobulin domains and three fibronectin domains). Amino acids 68-167 of H-Robo1 pep are the first immunoglobulin domain and correspond to amino acids 68-167 of SEQ ID NO:8 in the application.

In view of the foregoing, we respectfully submit that the evidence provided in this Declaration unequivocally establishes that the basic inventive concept of the claimed invention was conceived of and reduced to practice in this country prior to April 18, 1997.

We further declare that all statements made herein of our knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that any such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: \_\_\_\_\_

\_\_\_\_\_  
Corey S. Goodman

Dated: \_\_\_\_\_

\_\_\_\_\_  
Thomas Kidd

Dated: \_\_\_\_\_

\_\_\_\_\_  
Kevin J. Mitchell

Dated: 30/11/07

  
\_\_\_\_\_  
Guy Tear

MKWKHVPFLVMISLLSLSPNHLFLAQLIPDPEDVERGNDHGTPIPTSDNDDNSLG  
YTGSRLRQEDFPFPRIVEHPSDLIVSKGEPATLNCKAEGRPTPTIEWYKGGERVETD  
KDDPRSHRMLLPSSGSLFFLRIVHGRKSRPDEGVYVCVARNYLGEAVSHNASLEV  
AILRDDFRQNPSDVMVAVGEPAVMECQPPRGHPEPTISWKKDGSPLDDKDERITI  
RGGKLMITYTRKSDAGKYVCVGTNMVGERESEVAELTVLERPSFVKRPSNLAVT  
VDDSAEFKCEARGDPVPTVRWRKDDGELPKSRYEIRDDHTLTKIRKVTAGDMGSY  
TCVAENMVGKAEASATLTVQEPHFVVKPRDQVVALGRTVTFQCEATGNPQPAI  
FWRREGSQNLLFSYQPPQSSSRFSVSQTGDLTITNVQRSDVGYIICQTLNVAGSIIT  
KAYLEVTDVIADRPVVIRQGPVNQTVAVDGTFLVSCVATGSPVPTILWRKDGVL  
VSTQDSRIKQLENGVLQIRYAKLGDTGRYTCLASTPSGEATWSAYIEVQEFVGPV  
QPPRPTDPNLIPSAPSKPEVTDVSRNTVTLWSQPNLNSGATPTSIIIEAFSHASGSS  
WQTVAEENVKTETSAIKGLKPNAIYFLVRAANAYGISDPSQISDPVKTQDVLPTSQ  
GVDHKQVQRELGNVHLHNPTVLSSSSIEVHWTVDQQSQYIQGYKILYRPSGA  
NHGESDWLVFEVRTPAKNSVIPDLRKGVNYEIKARPFFNEFQOGADSEIKFAKTL  
EEAPSAPPQGVTVSKNDGNGTAILVSWQPPPEDTQNGMVQEYKVVWCLGNETRY  
HINKTVDGSTFSVIPFLVPGIRYSVEVAASTGAGSGVKSEPQFIQLDAHGNPVSPE  
DQVSLAQQISDVVKQPAFIAGIGAACWILMVFSIWLYRHRKKRNGLTSTYAGIRK  
VPSFTFTPTVTYQRGGEAVSSGGRPGLLNISEPAAQPWLADTWPNTGNNHNDCSI  
SCCTAGNGNSDSNLTTYSRPADCIANYNNQLDNKQTNLMLPESTVYGDVDLSNK  
INEMKTFNSPNLKDGRFVNPSGQPTPYATTQLIQSNLSNNMNNNGSGDSGEKHWK  
PLGQQKQEVAPVQYNIVEQNKLNKDYRANDTVPTIPYNQSYDQNTGGSYNSSD  
RGSSTSGSQGHKKGARTPKVPKQGGMNWADLLPPPAHPPPHSNSEEYNISVDES  
YDQEMPCPVPPARMYLQQDELEEEEDERGPTPPVRGAASSPAAVSYSHQSTATL  
TPSPQEELQPMLQDCPEETGHMQHQPDRRRQPVSPPPPPRPISPPHTYGYISGPLVS  
DMDTDAPEEEDEADMEVAKMQTRLLLRGLEQTPASSVGDLESSVTGSMING  
WGSASEEDNISSGRSSVSSSDGSFFTDADFAQAVAAAAEYAGLKVARRQMQDA  
AGRRHFHASQCPRPTSPVSTDSNMSAAVMQKTRPAKKLKHQPGHLRRETYTDD  
LPPPPVPPPAIKSPTAQSKTQLEVRPVVVPKLPSMDARTDKWRNGTTCPSFHCTR  
YVNI

## Exhibit A




Exhibit B